YH005 is an anti-Claudin 18.2 antibody generated using our Claudin 18.2 knock-out mice. We have out-licensed YH005 to RemeGen for the development of RC118. RC118 is a potentially first-in-class ADC (antibody-drug conjugate) for the treatment of solid tumors. It has obtained TGA approval for clinical trials in Australia and is currently under the IND application process in China.
